Business
Novo Nordisk and Eli Lilly Compete for GLP-1 Pill Market
Novo Nordisk and Eli Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage. The companies' long-standing rivalry is now focused on securing a larger share of this lucrative therapeutic area.
Coverage timeline — 1 article
CNBC
Novo Nordisk and Eli Lilly bring their longtime rivalry to GLP-1 pills and prepare to make their pitch to seniors with Medicare.
2026-06-08 14:30 UTC